Significant tumor reductions in neoadjuvant mss colon cancer patients treated with botensilimab/balstilimab presented at esmo gi conference

Lexington, mass.--(business wire)--agenus inc. (“agenus”) (nasdaq: agen), a leader in developing novel immunological agents to treat various cancers, today announced results from an investigator-sponsored trial (ist) of botensilimab and balstilimab (bot/bal) in the neoadjuvant setting for colon cancer. data were presented at the 2024 european society for medical oncology (esmo) gastrointestinal cancers congress in munich, germany. dr. pashtoon kasi, the originator of this groundbreaking study,.
MSS Ratings Summary
MSS Quant Ranking